Stein M, Neill P, Houston S, Davidson R
Department of Clinical Pharmacology, University of Zimbabwe, Harare.
Cent Afr J Med. 1990 Mar;36(3):72-5.
A recent survey of antibiotic prophylaxis found that local practice often differed from that recommended by authoritative bodies such as the British Society for Antimicrobial Chemotherapy (BSAC) and the American Heart Association (AHA). Practitioners found the subject confusing and requested guidance. For these reasons we present current recommendations. Unfortunately all recommendations are based on animal studies and an understanding of the pathogenesis of bacterial endocarditis in humans. There are no controlled trials in humans on which to base guidelines, so rigidity is inappropriate. It is also important to realise that optimal prophylaxis will not eliminate bacterial endocarditis. In developed countries it has been estimated that only 10% of cases of endocarditis are theoretically preventable.
最近一项关于抗生素预防的调查发现,当地的做法往往与英国抗菌化疗协会(BSAC)和美国心脏协会(AHA)等权威机构推荐的做法不同。从业者发现这个问题令人困惑,并请求提供指导。出于这些原因,我们给出当前的建议。遗憾的是,所有建议都基于动物研究以及对人类细菌性心内膜炎发病机制的理解。目前尚无基于人体对照试验的指南,因此过于严格并不合适。同样重要的是要认识到,最佳的预防措施并不能消除细菌性心内膜炎。据估计,在发达国家,理论上只有10%的心内膜炎病例是可以预防的。